IFNA1 and COVID-19: The outcome of COVID-19 was reversed by a 7-days hydroxychloroquine therapy, although, to date, there have been no robust clinical trials that have shown efficacy of these agents for this illness.[29] Notably, active SARS-CoV-2 infection was not associated with increased levels of IFNα and IFNβ gene expression and T cell immune activation compared to HIV-1-monoinfected women.